Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cadrenal TherapeuticsCVKD 30 PB Ratio is 2.83 as of Aug. 05, 2026. GuruFocus rates CVKD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Cadrenal Therapeutics ranks better than 50.65% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cadrenal Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadrenal Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cadrenal Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cadrenal Therapeutics (CVKD) has a PB Ratio of 2.83 as of Aug. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cadrenal Therapeutics and its competitors. According to the industry distribution chart, Cadrenal Therapeutics ranks #606 out of 1228 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Cadrenal Therapeutics' PB Ratio too high?
Cadrenal Therapeutics' current PB Ratio is 2.83. The Biotechnology industry median PB Ratio is 2.85. Cadrenal Therapeutics' value of 2.83 is 0.7% below this industry median. Based on the distribution chart, Cadrenal Therapeutics ranks #606 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cadrenal Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' PB Ratio compare to RVPH and IMNN?
According to the Biotechnology industry distribution chart, Cadrenal Therapeutics ranks #606 out of 1228 companies for PB Ratio. This puts Cadrenal Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.85. Cadrenal Therapeutics' value of 2.83 is 0.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.85, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cadrenal Therapeutics's current PB Ratio of 2.83 is 0.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cadrenal Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cadrenal Therapeutics's current PB Ratio is 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current PB Ratio of 2.83. The current PB Ratio is 2.83 and 0.7% below the Biotechnology industry median of 2.85. Cadrenal Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current PB Ratio is 2.83 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
30GF Score
Get the complete analysis for CVKD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVKD has been successfully added to your 
